Blueprint Medicines Corp (BPMC) reported quarterly earnings results on Tuesday, Aug-9-2016. The company said it had a profit of $-0.70 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $-0.73. The company posted revenue of $7.10 million in the period, compared to analysts expectations of $4.68 million. The company’s revenue was up 163.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.81 EPS.
Many Wall Street Analysts have commented on Blueprint Medicines Corp. Raymond James Initiated Blueprint Medicines Corp on May 27, 2016 to “Outperform”, Price Target of the shares are set at $23.
Blueprint Medicines Corp (BPMC) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $23.06 and reached the intraday high at $23.41. The bulls started the profit booking and pushed the shares to intraday low of $22.15. The trading session was marked by a volume range of 1,55,966 shares exchanging hands. The 52-week high of the shares is $31.9399 and the 52-week low is $13.04. The market cap of the company stands at $627 M and there are 2,72,38,661 shares in public circulation.
In a different news, on Jun 7, 2016, Jeffrey W. Albers (CEO and President) sold 17,000 shares at $20.03 per share price. According to the SEC, on Apr 14, 2016, Christoph Lengauer (Chief Scientific Officer) sold 15,872 shares at $20.01 per share price.
Blueprint Medicines Corporation (Blueprint) is a biopharmaceutical company. The Company is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. The Company developed a molecule drug pipeline in cancer and a genetic disease. Its lead drug candidate BLU-285 targets KIT Exon 17 and PDGFRa D842V active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. The Company’s BLU-285 is developed for patients with systemic mastocytosis (SM) and defined subsets of patients with gastrointestinal stromal tumor (GIST). The Company’s Imatinib which is an inhibitor of KIT and PDGFRa is approved in SM and GIST. The Company’s other drug candidate is BLU-554 which targets FGFR4 a kinase that is activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma. The Company is also developing a drug candidate to target both RET and RET resistant mutants.